

**Wanbury Limited**

**Regd. Office:** BSEL Tech Park, B-Wing, 10<sup>th</sup> Floor, Sector-30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai 400703 Maharashtra, INDIA  
Tel: +91-22-6794 2222  
+91-22-7196 3222  
CIN L51900MH1988PLC048455  
Email: info@wanbury.com  
Website: www.wanbury.com

October 12, 2026

|                                                                                                   |                                                                                                                                                         |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
| BSE Limited<br>PJ. Towers,<br>Dalal Street<br>Mumbai - 400 001.<br><br><b>Script Code:</b> 524212 | National Stock Exchange of India Ltd,<br>Exchange Plaza,<br>Bandra Kurla Complex,<br>Bandra (East), Mumbai -400 051.<br><br><b>Script Code:</b> WANBURY |
|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

Dear Sir/Madam,

**Sub.: Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its **berrysoft**™ baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.**

Pursuant to Regulation 30 of SEBI LODR, we wish to inform you as under:

Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches Its **berrysoft**™ baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.

**This is for your information and record & kindly ignore the previous press release.**

Thanking you.

**Yours faithfully,  
For Wanbury Limited**

JITENDRA  
JAYANTILAL  
GANDHI

**Jitendra J. Gandhi  
Company Secretary**



**Encl.: a/a**



## Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches Its **berrysoft™** baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment

Wanbury Limited, a pharmaceutical company with a global API presence and domestic branded formulations portfolio, today announced the launch of its **berrysoft™** baby product range across multiple states in India, through its subsidiary Wanbury Skin Health Limited.

The company has received GST registration in 5 states including Maharashtra, Delhi and Karnataka with three more in pipeline. The company also has received CFA Drug Licenses in Mumbai, Jaipur, Patna and Ambala with four more in pipeline.

The **berrysoft™** baby range has been developed to address everyday baby skincare and hygiene needs, with a portfolio comprising Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, Syndet Handwash already launched and Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream in pipeline. The range features dedicated formulations for different aspects of a baby's daily cleansing, moisturisation and skincare routine.





The launch represents Wanbury Skin Health Limited's strategic entry in the Paediatric Dermatology segment, **leveraging the company's existing relationships with paediatricians (doctors specialized in children practice)**. Through cross-selling to its established customer base, where Wanbury Limited already markets cold and cough products, the company aims to extend its engagement with paediatricians and broaden its presence in the paediatric healthcare segment. Wanbury Skin Health Limited will also focus on building relationships with dermatologists to strengthen its presence and drive growth in the dermatology segment.

The initiative reflects Wanbury Limited's focus on expanding its overall healthcare portfolio through its various subsidiaries, including Wanbury Skin Health Limited, which focuses on dermatology solutions for children and adults. By leveraging established market relationships, the company aims to drive growth in complementary product categories and strengthen its presence across relevant healthcare segments.

The multi-state launch marks an important milestone in Wanbury Limited's growth strategy, combining portfolio diversification with deeper engagement across its existing healthcare professional network. The company will continue to explore opportunities to broaden its product portfolio and strengthen its presence across relevant healthcare categories.

JITENDRA  
JAYANTILAL  
GANDHI

Digitally signed by JITENDRA JAYANTILAL GANDHI  
DN: c=IN, postalCode=400002, o=MANABADHYA  
JAYANTILAL, st=MAHARASHTRA, email=JITENDRA.JAYANTILAL@WANBURY.COM, ou=JITENDRA  
JAYANTILAL GANDHI  
Date: 2025.10.17 14:25:40 +05'30'